Sugi Predict

Sugi Predict / Compounds / Acetomenaphthone

Acetomenaphthone

Acetomenaphthone

SCHEMBL209382

CC(=O)Oc1cc(C)c(OC(C)=O)c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 1.00
▸ KDM4E B2RXH2 5/20 0.71
▸ HSD17B10 Q99714 3/20 0.71
▸ GAA P10253 3/20 0.71
▸ MAPT P10636 3/20 0.71
▸ TP53 P04637 1/20 0.71
▸ SLC22A6 Q4U2R8 1/20 0.50
▸ TSHR P16473 2/20 0.49
▸ POLB P06746 2/20 0.46
▸ TOP1 P11387 3/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ HPGD P15428 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ BLM P54132 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ ESR1 P03372 1/20 0.43
▸ ITGB3 P05106 1/20 0.43
▸ ITGA2B P08514 1/20 0.43
▸ HMGB1 P09429 1/20 0.43
▸ GGT1 P19440 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetomenaphthone SCHEMBL29411342 1.00 HTT (1.00) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL7918996 0.86 HTT (0.75) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL3597080 0.83 MAPT (1.00) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL11734972 0.82 HTT (0.69) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL9685110 0.81 HTT (0.69) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL9627465 0.81 HTT (0.69) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL10706901 0.81 HTT (0.68) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL20398637 0.80 HTT (0.67) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL30434021 0.80 HTT (0.67) HTTKDM4EHSD17B10GAAMAPT
SCHEMBL23271992 0.80 HTT (0.67) HTTKDM4EHSD17B10GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 711 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150283290-A1 STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES ADHEZION BIOMEDICAL, LLC (US) 2015-10-08 — — US claimed
CN-102503818-B Method for synthesizing menadiol acetate ANHUI WANHE PHARMACEUTICAL CO LTD 2015-01-07 — — CN claimed
CN-102503818-A Method for synthesizing menadiol acetate ANHUI WANHE PHARMACEUTICAL CO LTD 2012-06-20 — — CN claimed
JP-2010540159-A — — 2010-12-24 — — JP claimed
JP-2010509991-A — — 2010-04-02 — — JP claimed
EP-2086602-A2 DRUG RELEASING COATINGS FOR MEDICAL DEVICES Lutonix, Inc. (US) 2009-08-12 — — EP claimed
EP-2073860-A1 DRUG RELEASING COATINGS FOR MEDICAL DEVICES Lutonix, Inc. (US) 2009-07-01 — — EP claimed
EP-2066321-A2 TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS Lutonix, Inc. (US) 2009-06-10 — — EP claimed
WO-2009051614-A1 DRUG RELEASING COATINGS FOR MEDICAL DEVICES LUTONIX, INC. (US) 2009-04-23 — — WO claimed
US-20080255508-A1 Such as balloon and stents; medical device with overcoating of drug with additive; bioavailability LUTONIX, INC. 2008-10-16 — — US claimed
US-20080175887-A1 drug delivering by oral, nasal or pulmonary administration, of rapamycin or paclitaxel drug; additive enhances absorption of drug into body tissue; PEG-fatty acids esters, PEG-fatty alcohol ethers, polyethylene glycol sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers LUTONIX, INC. 2008-07-24 — — US claimed
WO-2008063581-A2 TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS LUTONIX, INC. (US) 2008-05-29 — — WO claimed
WO-2008063576-A2 DRUG RELEASING COATINGS FOR MEDICAL DEVICES LUTONIX, INC. (US) 2008-05-29 — — WO claimed
US-20080118544-A1 Such as a balloon catheter or a stent; a drug not enclosed in micelles or encapsulated in particles or controlled release carriers and an additive having hydrophobic and hydrophilic portions; improved pharmacokinetics and bioavailability LUTONIX, INC. 2008-05-22 — — US claimed
EP-1754712-A2 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2007-02-21 — — EP claimed
US-20060166862-A1 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation REGENTS OF THE UNIVERSITY OF MINNESOTA 2006-07-27 — — US claimed
EP-1334114-A2 TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2003-08-13 — — EP claimed
US-20020151525-A1 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation COLLINS DOUGLAS A (US) 2002-10-17 — — US claimed
WO-2002055530-A2 TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION MAYO FOUNDATION (US) 2002-07-18 — — WO claimed
US-4181719-A Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates STERLING DRUG INC. (US) 1980-01-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166862-A1 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation PCNA, MKI67, SLC19A1 HTT 3830/4885KDM4E 4872/4885HSD17B10 2144/4885
US-20020151525-A1 Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation PCNA, MKI67, SLC19A1 HTT 3830/4885KDM4E 4872/4885HSD17B10 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.